Multiple SclerosisPhase 1/2NCT07085507
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients
A Phase 1/2 study testing VT7208 in people with Multiple Sclerosis, run by Vidya Therapeutics Inc at 1 site in Australia.
Trial summary
Part 1 of this study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VT7208 in healthy volunteers. Part 2 of this study will be an open-label, randomized study to characterize the effect of food on the pharmacokinetics of VT7208 in healthy volunteers. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Multiple Sclerosis
- What is being tested?
- VT7208
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 1 siteAustralia
- Study dates
- 1 Aug 2025to 31 Dec 2027
- Phase
- Phase 1/2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Parts 1 and 2
- Age 18-65
- Must be in good health with no significant medical history
- Willing and able to attend all study visits and comply with study requirements, including lumbar puncture for CSF collection
- Able and willing to provide written informed consent
- Part 3
Show all 11Show fewer
- Age 18-60
- Must be in good health with no significant medical history
- MS diagnosis prior to Day 1 in accordance with 2017 McDonald criteria.
- Willing and able to attend all study visits and comply with study requirements, including lumbar puncture for CSF collection
- Able and willing to provide written informed consent
Who cannot join
- Evidence of clinically significant condition or disease
- Any physical or psychological condition that prohibits study completion
- Known history of illicit drug use or drug abuse, harmful alcohol use (at the -Investigator's discretion), alcoholism, and/or smoking or nicotine-containing product use within 7 days prior to the first dose of study agent
- History of severe allergic reactions or hypersensitivity
- Donation or loss of ≥ 1 unit of whole blood or plasma within 4 weeks prior to dosing
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Australia1 site, 1 recruiting
- Recruiting
CMAX
Adelaide, South Australia, 5000
Katherine Mudge, +61 (0)8 7088 7900, katherine.mudge@cmax.com.au
About this study
Official title: A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Escalation Study in Healthy Participants and an Expansion Cohort in Adult Patients With Multiple Sclerosis to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208
Part 1 of this study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VT7208 in healthy volunteers.
Part 2 of this study will be an open-label, randomized study to characterize the effect of food on the pharmacokinetics of VT7208 in healthy volunteers.
Part 3 of this study will evaluate the safety of VT7208 as monotherapy in patients with MS.
Read the detailed description
This study is a Phase 1/2 randomized, double-blind, placebo-controlled, single- and multiple-dose study with staggered dose escalations in healthy volunteers.
Following completion of SAD and MAD cohorts, healthy volunteers will participate in administration of VT7208 with and without food to determine the effect of a fasted or fed state on pharmacokinetics.
Participants with MS will be recruited for part 3 of this study.
This study consists of 3 parts, as follows:
Part 1: SAD in healthy volunteers with a single dose administration of VT7208 or placebo and collection of study data.
MAD in healthy volunteers with multiple dose administration of VT7208 or placebo and collection of study data.
Part 2:
Food effect cohort in healthy volunteers. Participants will be randomized to receive open label VT7208 in either a fasted state or a fed state, and will receive the opposite at the next admission to the study site.
Part 3:
Participants MS will receive VT7208 with dose determined from Parts 1 and 2. Participation in this section will entail weekly study visits for administration of study medication and collection of study data.
- Conditions
- Multiple Sclerosis
- Being tested
- VT7208, Placebo
- Keywords
- pharmacokinetics, healthy volunteers, pharmacodynamics, central nervous system
- Medical subject headings
- Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VT7208Drug
a small synthetic molecule capsule, oral
PlaceboDrug
capsule, oral
| Study group | Role | What they receive |
|---|---|---|
| Part 1 SAD Cohorts: Active drug | Experimental | Participants will receive a single dose of VT7208 in a dose escalation format. Receives: Drug: VT7208 |
| Part 1 SAD Cohorts: Placebo | Placebo comparator | Healthy volunteers will receive a single dose of placebo Receives: Drug: Placebo |
| Part 1 MAD Cohort: Active drug | Experimental | Healthy volunteers will receive repeated doses of VT7208. Dose to be determined based on escalation data from SAD Cohorts Receives: Drug: VT7208 |
| Part 1 MAD Cohort: Placebo | Placebo comparator | Healthy volunteers will receive repeated doses of placebo comparator. Receives: Drug: Placebo |
| Part 2: Food Effect | Experimental | Open label randomized cohort to be administered to healthy volunteers. Participants will be randomized to receive dose in either fasted or fed state. Dose to be determined from data of SAD and MAD cohorts. Receives: Drug: VT7208 |
| Part 3: Patients with Multiple Sclerosis | Experimental | Open label cohort to be administered to patients with MS. Dose for this part will be determined from parts 1 and 2. Receives: Drug: VT7208 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of VT7208 in healthy volunteers receiving a single dose.
To assess the incidence, nature, and relationship of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) in healthy adults following a single dose.
Measured: Up to 8 days
Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of VT7208 in healthy volunteers who receive multiple daily doses.
To assess the incidence, nature, and relationship of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) in healthy adults following multiple daily doses.
Measured: Up to 16 days
Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of daily VT7208 in patients with MS
To assess the incidence, nature, and relationship of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) in patients with Multiple Sclerosis (MS).
Measured: Up to 16 weeks
Secondary outcomes (21)
Pharmacokinetics of a single dose of VT7208-Cmax
PK parameters of VT7208 on concentrations in plasma following a single dose in healthy volunteers. Cmax represents the maximum (or peak) concentration of a drug in the blood plasma after it has been administered and distributed, but before the next dose
Measured: up to 8 days
Pharmacokinetics of a single dose of VT7208-T 1/2
PK parameters of VT7208 on concentrations in plasma following a single dose in healthy volunteers. T 1/2 represents the half-life of a drug, which is the time required for the concentration of a medication in the blood to decrease by exactly 50%
Measured: up to 8 days
Pharmacokinetics of a single dose of VT7208-Tmax
PK parameters of VT7208 on concentrations in plasma following a single dose in healthy volunteers. Tmax is the time required for a drug to reach its maximum concentration in the blood or plasma after it is administered. It is a crucial measurement used by researchers and clinicians to evaluate how quickly the body absorbs a medication and when its therapeutic effects will begin.
Measured: up to 8 days
Pharmacokinetics of a single dose of VT7208 fed state: Cmax
PK parameters of VT7208 on concentrations in plasma following a single dose in healthy volunteers in a fed state. Cmax represents the maximum (or peak) concentration of a drug in the blood plasma after it has been administered and distributed, but before the next dose
Measured: up to 8 days
Pharmacokinetics of a single dose of VT7208 fed state: T 1/2
PK parameters of VT7208 on concentrations in plasma following a single dose in healthy adults in a fed state. T 1/2 represents the half-life of a drug, which is the time required for the concentration of a medication in the blood to decrease by exactly 50%
Measured: up to 8 days
Pharmacokinetics of a single dose of VT7208 fed state: Tmax
PK parameters of VT7208 on concentrations in plasma following a single dose in healthy volunteers in a fed state. Tmax is the time required for a drug to reach its maximum concentration in the blood or plasma after it is administered. It is a crucial measurement used by researchers and clinicians to evaluate how quickly the body absorbs a medication and when its therapeutic effects will begin.
Measured: up to 8 days
Pharmacokinetics of a single dose of VT7208 fasted state: Cmax
PK parameters of VT7208 on concentrations in plasma following a single dose in healthy volunteers in a fasted state. Cmax represents the maximum (or peak) concentration of a drug in the blood plasma after it has been administered and distributed, but before the next dose
Measured: up to 8 days
Pharmacokinetics of a single dose of VT7208 fasted state: T 1/2
PK parameters of VT7208 on concentrations in plasma following a single dose in healthy adults in a fasted state. T 1/2 represents the half-life of a drug, which is the time required for the concentration of a medication in the blood to decrease by exactly 50%
Measured: up to 8 days
Pharmacokinetics of a single dose of VT7208 fasted state: Tmax
PK parameters of VT7208 on concentrations in plasma following a single dose in healthy volunteers in a fasted state. Tmax is the time required for a drug to reach its maximum concentration in the blood or plasma after it is administered. It is a crucial measurement used by researchers and clinicians to evaluate how quickly the body absorbs a medication and when its therapeutic effects will begin.
Measured: up to 8 days
Pharmacokinetics of a multiple doses of VT7208-Cmax
PK parameters of VT7208 on concentrations in plasma following multiple doses in healthy volunteers. Cmax represents the maximum (or peak) concentration of a drug in the blood plasma after it has been administered and distributed, but before the next dose
Measured: up to 16 days
Pharmacokinetics of a multiple doses of VT7208-T 1/2
PK parameters of VT7208 on concentrations in plasma following multiple doses in healthy volunteers. T 1/2 represents the half-life of a drug, which is the time required for the concentration of a medication in the blood to decrease by exactly 50%
Measured: up to 16 days
Pharmacokinetics of a multiple doses of VT7208-T max
PK parameters of VT7208 on concentrations in plasma following multiple doses in healthy volunteers. Tmax is the time required for a drug to reach its maximum concentration in the blood or plasma after it is administered. It is a crucial measurement used by researchers and clinicians to evaluate how quickly the body absorbs a medication and when its therapeutic effects will begin.
Measured: up to 16 days
Pharmacokinetics of VT7208 in patients with Multiple Sclerosis-Cmax
PK parameters of VT7208 on concentrations in plasma in participants with Multiple Sclerosis (MS). Cmax represents the maximum (or peak) concentration of a drug in the blood plasma after it has been administered and distributed, but before the next dose
Measured: up to 16 weeks
Pharmacokinetics of VT7208 in patients with Multiple Sclerosis-T 1/2
PK parameters of VT7208 on concentrations in plasma in participants with Multiple Sclerosis (MS). T 1/2 represents the half-life of a drug, which is the time required for the concentration of a medication in the blood to decrease by exactly 50%
Measured: up to 16 weeks
Pharmacokinetics of VT7208 in patients with Multiple Sclerosis-Tmax
PK parameters of VT7208 on concentrations in plasma in participants with Multiple Sclerosis (MS). Tmax is the time required for a drug to reach its maximum concentration in the blood or plasma after it is administered. It is a crucial measurement used by researchers and clinicians to evaluate how quickly the body absorbs a medication and when its therapeutic effects will begin.
Measured: up to 16 weeks
Pharmacodynamics of a single dose of VT7208 in healthy volunteers
Pharmacodynamic parameters of VT7208 following a single dose in healthy volunteers. Pharmacodynamic markers are proteins that represent disease progression in MS, and will be measured by concentration of proteins within the blood.
Measured: up to 8 days
Pharmacodynamics of a multiple doses of VT7208 in healthy volunteers
Pharmacodynamic parameters of VT7208 following multiple doses in healthy volunteers. Pharmacodynamic markers are proteins that represent disease progression in MS, and will be measured by concentration of proteins within the blood.
Measured: up to 16 days
Pharmacodynamics of VT7208 in patients with Multiple Sclerosis
Pharmacodynamic parameters of VT7208 in participants with Multiple Sclerosis (MS). Pharmacodynamic markers are proteins that represent disease progression in MS, and will be measured by concentration of proteins within the blood.
Measured: up to 16 weeks
Characterize the ability of VT7208 to cross the blood brain barrier in healthy volunteers following a single dose
Concentration of VT7208 will be measured in cerebrospinal fluid (CSF) in healthy volunteers following a single dose.This will be measured in concentration of VT7208 within the CSF. Presence will indicate the ability of VT7208 to cross the blood/brain barrier.
Measured: up to 8 days
Characterize the ability of VT7208 to cross the blood brain barrier in healthy volunteers following multiple doses
Concentration of VT7208 will be measured in cerebrospinal fluid (CSF) in healthy volunteers following multiple doses.This will be measured in concentration of VT7208 within the CSF Presence will indicate the ability of VT7208 to cross the blood/brain barrier.
Measured: up to 16 days
Characterize the ability of VT7208 to cross the blood brain barrier in patients with MS
Concentration of VT7208 will be measured in cerebrospinal fluid (CSF) in patients with Multiple Sclerosis (MS). This will be measured in concentration of VT7208 within the CSF. Presence will indicate the ability of VT7208 to cross the blood/brain barrier.
Measured: up to 16 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jul 2025
- Study start1 Aug 2025
- Primary completion30 Oct 2026 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Vidya Therapeutics Inc
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Vidya Therapeutics Australia Pty Ltd
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07085507
- Sponsor's protocol ID
- VT7208-101
- Status last verified
- Jul 2026
- First submitted
- 7 Jul 2025
- Last updated
- 21 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Escalation Study in Healthy Participants and an Expansion Cohort in Adult Patients With Multiple Sclerosis to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208
- ClinicalTrials.gov ID
- NCT07085507
- Acronym / sponsor ID
- VT7208-101
- Conditions
- Multiple Sclerosis
- Keywords
- pharmacokinetics, healthy volunteers, pharmacodynamics, central nervous system
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Vidya Therapeutics IncIndustry (pharma, biotech, devices)
- Collaborators
- Vidya Therapeutics Australia Pty Ltd
- Study start
- 1 Aug 2025 (actual)
- Primary completion
- 30 Oct 2026 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 25 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Part 1 of this study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VT7208 in healthy volunteers.
Part 2 of this study will be an open-label, randomized study to characterize the effect of food on the pharmacokinetics of VT7208 in healthy volunteers.
Part 3 of this study will evaluate the safety of VT7208 as monotherapy in patients with MS.
Detailed description
This study is a Phase 1/2 randomized, double-blind, placebo-controlled, single- and multiple-dose study with staggered dose escalations in healthy volunteers.
Following completion of SAD and MAD cohorts, healthy volunteers will participate in administration of VT7208 with and without food to determine the effect of a fasted or fed state on pharmacokinetics.
Participants with MS will be recruited for part 3 of this study.
This study consists of 3 parts, as follows:
Part 1: SAD in healthy volunteers with a single dose administration of VT7208 or placebo and collection of study data.
MAD in healthy volunteers with multiple dose administration of VT7208 or placebo and collection of study data.
Part 2:
Food effect cohort in healthy volunteers. Participants will be randomized to receive open label VT7208 in either a fasted state or a fed state, and will receive the opposite at the next admission to the study site.
Part 3:
Participants MS will receive VT7208 with dose determined from Parts 1 and 2. Participation in this section will entail weekly study visits for administration of study medication and collection of study data.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Part 1 SAD Cohorts: Active drug | Experimental | Drug: VT7208Participants will receive a single dose of VT7208 in a dose escalation format. |
| Part 1 SAD Cohorts: Placebo | Placebo comparator | Drug: PlaceboHealthy volunteers will receive a single dose of placebo |
| Part 1 MAD Cohort: Active drug | Experimental | Drug: VT7208Healthy volunteers will receive repeated doses of VT7208. Dose to be determined based on escalation data from SAD Cohorts |
| Part 1 MAD Cohort: Placebo | Placebo comparator | Drug: PlaceboHealthy volunteers will receive repeated doses of placebo comparator. |
| Part 2: Food Effect | Experimental | Drug: VT7208Open label randomized cohort to be administered to healthy volunteers. Participants will be randomized to receive dose in either fasted or fed state. Dose to be determined from data of SAD and MAD cohorts. |
| Part 3: Patients with Multiple Sclerosis | Experimental | Drug: VT7208Open label cohort to be administered to patients with MS. Dose for this part will be determined from parts 1 and 2. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Parts 1 and 2
- Age 18-65
- Must be in good health with no significant medical history
- Willing and able to attend all study visits and comply with study requirements, including lumbar puncture for CSF collection
- Able and willing to provide written informed consent
Key exclusion criteria (5 listed)
- Evidence of clinically significant condition or disease
- Any physical or psychological condition that prohibits study completion
- Known history of illicit drug use or drug abuse, harmful alcohol use (at the -Investigator's discretion), alcoholism, and/or smoking or nicotine-containing product use within 7 days prior to the first dose of study agent
- History of severe allergic reactions or hypersensitivity
- Donation or loss of ≥ 1 unit of whole blood or plasma within 4 weeks prior to dosing
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VT7208a small synthetic molecule capsule, oral | Drug | Part 1 MAD Cohort: Active drug, Part 1 SAD Cohorts: Active drug, Part 2: Food Effect, Part 3: Patients with Multiple Sclerosis |
| Placebocapsule, oral | Drug | Part 1 MAD Cohort: Placebo, Part 1 SAD Cohorts: Placebo |
Primary outcome
Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of VT7208 in healthy volunteers receiving a single dose.
Time frame: Up to 8 days
To assess the incidence, nature, and relationship of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) in healthy adults following a single dose.
Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of VT7208 in healthy volunteers who receive multiple daily doses.
Time frame: Up to 16 days
To assess the incidence, nature, and relationship of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) in healthy adults following multiple daily doses.
Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of daily VT7208 in patients with MS
Time frame: Up to 16 weeks
To assess the incidence, nature, and relationship of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) in patients with Multiple Sclerosis (MS).
21 secondary outcomes
Pharmacokinetics of a single dose of VT7208-Cmax
Time frame: up to 8 days
Pharmacokinetics of a single dose of VT7208-T 1/2
Time frame: up to 8 days
Pharmacokinetics of a single dose of VT7208-Tmax
Time frame: up to 8 days
Pharmacokinetics of a single dose of VT7208 fed state: Cmax
Time frame: up to 8 days
Pharmacokinetics of a single dose of VT7208 fed state: T 1/2
Time frame: up to 8 days
Pharmacokinetics of a single dose of VT7208 fed state: Tmax
Time frame: up to 8 days
Pharmacokinetics of a single dose of VT7208 fasted state: Cmax
Time frame: up to 8 days
Pharmacokinetics of a single dose of VT7208 fasted state: T 1/2
Time frame: up to 8 days
Pharmacokinetics of a single dose of VT7208 fasted state: Tmax
Time frame: up to 8 days
Pharmacokinetics of a multiple doses of VT7208-Cmax
Time frame: up to 16 days
Pharmacokinetics of a multiple doses of VT7208-T 1/2
Time frame: up to 16 days
Pharmacokinetics of a multiple doses of VT7208-T max
Time frame: up to 16 days
Pharmacokinetics of VT7208 in patients with Multiple Sclerosis-Cmax
Time frame: up to 16 weeks
Pharmacokinetics of VT7208 in patients with Multiple Sclerosis-T 1/2
Time frame: up to 16 weeks
Pharmacokinetics of VT7208 in patients with Multiple Sclerosis-Tmax
Time frame: up to 16 weeks
Pharmacodynamics of a single dose of VT7208 in healthy volunteers
Time frame: up to 8 days
Pharmacodynamics of a multiple doses of VT7208 in healthy volunteers
Time frame: up to 16 days
Pharmacodynamics of VT7208 in patients with Multiple Sclerosis
Time frame: up to 16 weeks
Characterize the ability of VT7208 to cross the blood brain barrier in healthy volunteers following a single dose
Time frame: up to 8 days
Characterize the ability of VT7208 to cross the blood brain barrier in healthy volunteers following multiple doses
Time frame: up to 16 days
Characterize the ability of VT7208 to cross the blood brain barrier in patients with MS
Time frame: up to 16 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jul 2026.
Related trials for Multiple Sclerosis
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
RecruitingPhase 3
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Multiple Sclerosis
RecruitingPhase 2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing VT7208 in people with Multiple Sclerosis, run by Vidya Therapeutics Inc at 1 site in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact MIchele DeSciscio, MBSS (+61 (0) 422 447 902, Michele.DeSciscio@cmax.com.au), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of VT7208 in healthy volunteers receiving a single dose. (time frame: Up to 8 days). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2026.